01 DNT cells are prepared from the peripheral blood of healthy donors at low cost, with a standardized production procedure that allows them to be prepared in advance, frozen and be provided as an "off-the-shelf" immunotherapy product.

DNT cell products are a true off-the-shelf general-purpose immunotherapy product with expansive clinical accessibility and significant commercial development value.

DNT cell products from healthy donors can be prepared on a large scale in a standardized manner. This greatly guarantees the quality stability of RC1012 (DNT product in clinical trial) from batch to batch.

02 DNT cells are compatible with allogeneic hematopoietic stem cell transplantations, small molecule antitumor drugs, and immune checkpoint inhibitors. As a global innovative immune cell therapy that can be combined with these existing therapies, this "off-the-shelf" immunotherapy product has demonstrated in clinical trials for its safety and promising antitumor activities. To further advance its development is warranted.

03 A series of off-the-shelf generic CAR-DNT Immunotherapy products has been developed by direct transduction of the CAR genes.

A variety of off-the-shelf generic immunotherapy products have been developed by the CAR-DNT cell technology platform. RJMty19, the CD19-CAR-DNT product is now in clinical trials for the treatment of hematological tumors and autoimmune diseases by exerting the triple tumor-killing activity through TCRs, NCRs, and CARs.

04 DNT cells can further enhance tumor infiltration ability to clear tumor cells via gene editing.

The CRISPR/Cas12a gene editing with the intellectual property protected technologies further enhances the tumor-killing ability of DNT cells by knocking out a specific gene target like PD-1 gene and others.